I. Maestu

1.2k total citations
49 papers, 884 citations indexed

About

I. Maestu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, I. Maestu has authored 49 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in I. Maestu's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (17 papers) and Colorectal Cancer Treatments and Studies (14 papers). I. Maestu is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (17 papers) and Colorectal Cancer Treatments and Studies (14 papers). I. Maestu collaborates with scholars based in Spain, Palestinian Territory and Italy. I. Maestu's co-authors include José Gómez‐Codina, Jorge Aparicio, José María Tenías, R. Blanco, Regina Gironés, Alfredo Carrato, Rafael Rosell, Albert Abad, Enrique Aranda and Eduardo Díaz‐Rubio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

I. Maestu

48 papers receiving 862 citations

Peers

I. Maestu
G.P. Nicolella Italy
Toshiki Masuishi Japan
Christelle Clément-Duchêne France
Megan Kennedy Ireland
Leïla Bengrine-Lefèvre France
Giuseppe De Cataldis Italy
Barbara Graham Canada
A.C. Braud France
Yukiya Narita Japan
Christophe Desauw France
G.P. Nicolella Italy
I. Maestu
Citations per year, relative to I. Maestu I. Maestu (= 1×) peers G.P. Nicolella

Countries citing papers authored by I. Maestu

Since Specialization
Citations

This map shows the geographic impact of I. Maestu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Maestu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Maestu more than expected).

Fields of papers citing papers by I. Maestu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Maestu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Maestu. The network helps show where I. Maestu may publish in the future.

Co-authorship network of co-authors of I. Maestu

This figure shows the co-authorship network connecting the top 25 collaborators of I. Maestu. A scholar is included among the top collaborators of I. Maestu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Maestu. I. Maestu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guilabert, Mercedes, Joan Prades, Josep M. Borràs, et al.. (2021). A Web-Based Self-assessment Model for Evaluating Multidisciplinary Cancer Teams in Spain: Development and Validation Pilot Study. Journal of Medical Internet Research. 24(3). e29063–e29063. 3 indexed citations
2.
Maestu, I., et al.. (2020). Cognitive impairment is related to a reduced count of T-lymphocytes in older patients diagnosed with non-small cell lung cancer (NSCLC). Translational Cancer Research. 9(11). 6857–6866. 8 indexed citations
3.
Maestu, I., et al.. (2020). Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy. Clinical & Translational Oncology. 22(12). 2333–2340. 8 indexed citations
4.
Sesé, Marta, Rosa Somoza, I. Maestu, et al.. (2019). Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients. SHILAP Revista de lepidopterología. 7(2). 131–139. 1 indexed citations
5.
Remón, Jordi, Dolores Isla, Pilar Garrido, et al.. (2017). Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clinical & Translational Oncology. 19(12). 1537–1542. 4 indexed citations
6.
Blanco, R., et al.. (2014). A review of the management of elderly patients with non-small-cell lung cancer. Annals of Oncology. 26(3). 451–463. 69 indexed citations
7.
Gironés, Regina, et al.. (2012). Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians. Clinical & Translational Oncology. 14(3). 183–189. 39 indexed citations
8.
Isla, Dolores, Mariano Provencio, Margarita Majem, et al.. (2012). Never-smoking women with lung cancer from the Spanish WORLD07 database.. Journal of Clinical Oncology. 30(15_suppl). 1531–1531. 1 indexed citations
9.
Merino‐Sanjuán, Matilde, et al.. (2011). Effect of Age on Systemic Exposure and Haematological Toxicity of Carboplatin in Advanced Non-Small Cell Lung Cancer Patients. Basic & Clinical Pharmacology & Toxicology. 109(6). 457–464. 4 indexed citations
10.
Viñolas, Núria, Mariano Provencio, Noemı́ Reguart, et al.. (2010). Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 71(2). 191–198. 39 indexed citations
11.
Gironés, Regina, et al.. (2010). Prognostic impact of comorbidity in elderly lung cancer patients: Use and comparison of two scores. Lung Cancer. 72(1). 108–113. 38 indexed citations
12.
Sastre, Javier, Enrique Aranda, Bartomeu Massutí, et al.. (2008). Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. Critical Reviews in Oncology/Hematology. 70(2). 134–144. 40 indexed citations
13.
Martinez‐Balibrea, Eva, Albert Abad, Enrique Aranda, et al.. (2008). Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. European Journal of Cancer. 44(9). 1229–1237. 58 indexed citations
14.
15.
Aparicio, Jorge, et al.. (2005). FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 5(4). 263–267. 29 indexed citations
16.
Aparicio, Jorge, I. Maestu, António Galán de Mera, et al.. (2005). First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer. Oncology. 68(1). 58–63. 11 indexed citations
17.
Aparicio, Jorge, I. Maestu, C. Bosch, et al.. (2003). Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Annals of Oncology. 14(7). 1121–1125. 19 indexed citations
18.
19.
Montalar, Joaquín, Serafín Morales, I. Maestu, et al.. (2001). Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. Lung Cancer. 34(2). 305–311. 8 indexed citations
20.
Maestu, I., María A. Pastor, José Gómez‐Codina, et al.. (1997). Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients. Annals of Oncology. 8(6). 547–553. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.P. Nicolella Breakdown of academic impact, for papers by Toshiki Masuishi Breakdown of academic impact, for papers by Christelle Clément-Duchêne Breakdown of academic impact, for papers by Megan Kennedy Breakdown of academic impact, for papers by Leïla Bengrine-Lefèvre Breakdown of academic impact, for papers by Giuseppe De Cataldis Breakdown of academic impact, for papers by Barbara Graham Breakdown of academic impact, for papers by A.C. Braud Breakdown of academic impact, for papers by Yukiya Narita Breakdown of academic impact, for papers by Christophe Desauw
Rankless by CCL
2026